Quick View
| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue | ¥242.6B | ¥243.1B | −0.2% |
| Operating Income | ¥2.1B | ¥3.5B | −41.7% |
| Ordinary Income | ¥2.1B | ¥3.5B | −39.8% |
| Net Income | ¥2.9B | ¥0.3B | +709.5% |
| ROE | 1.5% | 0.2% | - |
Executive Summary
Cumulative results for Q3 FY2026 recorded revenue of ¥242.6B (YoY -¥0.5B, -0.2%), remaining roughly flat, while operating income was ¥2.1B (YoY -¥1.4B, -41.7%) and ordinary income was ¥2.1B (YoY -¥1.4B, -39.8%), both declining significantly. Meanwhile, net income improved markedly to ¥2.9B (up ¥2.6B from ¥0.3B in the prior-year period). The operating margin fell to 0.9% (down 0.5pt from 1.4% in the prior-year period). The improvement in net income was supported by recording a ¥1.6B gain on sale of marketable securities, although a ¥2.6B valuation loss on investment securities also occurred. The full-year guidance remains for revenue of ¥335.0B (YoY +2.9%), operating income of ¥3.0B (YoY -49.5%), ordinary income of ¥1.0B (YoY -77.4%), and net income of ¥1.5B (YoY -66.5%), indicating an outlook for lower earnings.
Key Financial Indicators
[Profitability] ROE 1.5% (improved from 0.2% in the prior-year period, but relatively low versus the company’s 3-year average), operating margin 0.9% (down 0.5pt from 1.4% in the prior-year period), net margin 1.2% (up 1.1pt from 0.1% in the prior-year period), and an EBIT margin of 0.8% indicate extremely low profitability. [Cash Quality] Cash and deposits ¥34.3B; cash coverage of short-term liabilities is 1.88x, securing short-term liquidity. Interest coverage of 1.22x indicates vulnerability in debt service capacity. [Investment Efficiency] Total asset turnover 0.47x and ROIC 0.6% reflect low capital efficiency. Total assets increased to ¥521.0B, up ¥22.5B YoY. [Financial Soundness] Equity ratio 36.9% (down 1.6pt from 38.5% in the prior-year period), current ratio 228.0%, and quick ratio 176.9% indicate sound liquidity. Debt-to-equity ratio 1.71x, interest-bearing debt ¥133.4B, and Debt-to-Capital ratio 40.9%. Short-term borrowings were ¥3.9B, up ¥1.6B (+69.6%) from ¥2.3B in the prior-year period, indicating a shortening of the maturity profile.
Cash Flow Analysis
Cash and deposits increased by ¥8.0B YoY to ¥34.3B, which is estimated to have been supported by higher operating profit and the sale of marketable securities as funding sources. In working capital, accounts receivable at ¥78.2B and inventories at ¥72.7B account for a large share of current assets, making inventory turnover and receivables collection key drivers of capital efficiency. Cash coverage of short-term liabilities is 1.88x, ensuring sufficient short-term payment capacity. Meanwhile, short-term borrowings surged by +69.6% YoY, requiring attention to changes in maturity structure and refinancing risk. With interest expense of ¥1.7B and operating income of ¥2.1B, interest coverage is limited to 1.22x, indicating that interest burden is structurally squeezing earnings. Regarding the funding source for dividend payments, while the cash balance and net income level suggest short-term capacity, the sustainability of coverage is difficult to assess because details of operating cash flow (OCF) are undisclosed.
Quality of Earnings
With ordinary income at ¥2.1B and operating income at ¥2.1B, non-operating gains and losses are roughly balanced. Non-operating income of ¥2.0B mainly comprises dividend income received and interest income, while non-operating expenses of ¥2.0B are largely interest expense of ¥1.7B. In extraordinary items, a ¥1.6B gain on sale of marketable securities was recorded, while a ¥2.6B valuation loss on investment securities occurred, resulting in net extraordinary losses. Net income of ¥2.9B exceeded operating income due to the contribution of extraordinary gains, but earnings power generated from operating income remains fragile. Non-operating income accounts for 0.8% of revenue, and extraordinary gains account for 0.6%, indicating that non-recurring factors have a certain impact on the profit mix. While the details of OCF are undisclosed and the cash backing of earnings cannot be directly confirmed, the increase in cash balance indicates a certain cash generation capability.
Risk Factors
- Operating margin at 0.9% is extremely low, with high SG&A levels limiting operating leverage. The full-year outlook also projects operating income of ¥3.0B, a YoY decline of -49.5%, suggesting structurally low profitability will persist unless addressed.
- Interest coverage of 1.22x indicates weak debt service capacity. With interest expense of ¥1.7B against operating income of ¥2.1B, the margin of safety is thin, and fluctuations in operating income directly affect the ability to service interest.
- Short-term borrowings increased by +69.6% YoY, shortening the maturity profile. Repayment and refinancing risks are rising, increasing liquidity risk amid changes in interest rate conditions or deterioration in funding terms.
Industry Benchmark (Reference, In-house Research)
[Position within Industry] (Reference information, in-house research) Compared with the pharmaceuticals industry (N=6 companies) as of Q3 2025, the following characteristics are observed. Profitability: The operating margin of 0.9% is well above the industry median of -189.5%, maintaining profitability, but this represents relative outperformance within an industry experiencing significant losses overall. The net margin of 1.2% also exceeds the industry median of -191.3%. Soundness: The equity ratio of 36.9% is well below the industry median of 68.2%, indicating relatively low capital accumulation within the industry. Liquidity: The current ratio of 228.0% is below the industry median of 610.0%, indicating a relatively thin liquidity buffer within the industry. Efficiency: ROE of 1.5% significantly exceeds the industry median of -48.8%, showing an advantage in terms of capital efficiency by maintaining profitability. The revenue growth rate of -0.2% is above the industry median of -10.8%, indicating maintenance of sales scale within the industry. While the pharmaceuticals industry as a whole includes many loss-making companies due to R&D investments, the company remains profitable; however, the absolute levels of profitability and capital efficiency are low, and its relative advantage within the industry is limited (Industry: Pharmaceuticals (6 companies), Comparison: Q3 2025, Source: In-house aggregation).
Key Takeaways from Results
There are two key takeaways from the results. First, the operating margin remains extremely low at 0.9%, and the full-year outlook also projects operating income of ¥3.0B (YoY -49.5%), indicating lower earnings. Elevated SG&A levels and a lack of operating leverage persist as structural issues for profitability; absent improved SG&A efficiency and a higher mix of high value-added products, margin improvement will be difficult. Second, with interest coverage at 1.22x indicating weak debt service capacity, short-term borrowings increased by +69.6% YoY, shortening the maturity profile. The simultaneous presence of low operating income levels and heavy interest burden reduces resilience to changes in OCF and funding conditions, making improvements in operating efficiency and a review of the financial structure pressing issues.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. The industry benchmark is reference information aggregated by our company based on publicly available earnings data. Investment decisions are your own responsibility; please consult a professional as necessary before making any investment decisions.
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was operationally weak despite a sharp increase in reported net income. Revenue was broadly flat at ¥24.26bn, down 0.2% year on year. Gross profit declined 3.5% to ¥6.26bn as the gross margin contracted to 25.8% from 26.7%, a deterioration of approximately 90 basis points. SG&A expenses declined 1.3% to ¥6.05bn, but the reduction was insufficient to offset the gross-profit decline. Operating income fell 41.7% to ¥0.21bn. The operating margin compressed by approximately 61 basis points to 0.9% from 1.5%. Ordinary income similarly declined 39.8% to ¥0.21bn, indicating that the core earnings pressure extended below the operating line. Net income increased 709.5% to ¥0.29bn, but this was principally supported by a ¥0.16bn gain on sales of investment securities. The ¥0.10bn foreign-exchange gain was also material, equivalent to 49.3% of operating income. Consequently, the 1.2% net margin and 2.0% reported ROE overstate the underlying operating profitability. Interest expense of ¥0.17bn absorbed a substantial portion of EBIT, leaving interest coverage at only 1.22x. Liquidity remains sound, with a 228.0% current ratio and ¥18.22bn of working capital. However, the balance sheet carries ¥13.34bn of interest-bearing debt and a 1.71x debt-to-equity ratio, making the low operating-profit base a central credit consideration. The company has achieved 72.4% of its full-year sales forecast and 69.0% of its operating-income forecast after nine months, both moderately below the standard 75% Q3 pace. In contrast, ordinary income and net income already exceed the respective full-year forecasts, reflecting non-recurring gains rather than an improvement in recurring earnings capacity. The key implication for the final quarter is that the company needs to protect gross margin, reduce working-capital intensity, and restore interest coverage through a recovery in operating profit rather than reliance on asset-sale and FX-related gains.
Profitability Analysis
DuPont analysis shows reported ROE of 2.0%, composed of a 1.2% net profit margin, 0.621x annualized asset turnover, and 2.71x financial leverage. The primary constraint is the low earnings margin rather than asset utilization or leverage: EBIT margin was only 0.8% on the reported extended DuPont measure, while the operating margin was approximately 0.9%. Financial leverage supports reported ROE, but leverage cannot compensate for a sub-1% operating-margin structure on a sustainable basis. Gross margin fell to 25.8% from 26.7%, while SG&A as a proportion of revenue improved modestly to approximately 24.9% from 25.2%. This means that the major deterioration occurred at the gross-profit level, not because SG&A rose faster than sales. Operating income declined by ¥0.15bn, substantially faster than the ¥0.05bn revenue decline, demonstrating unfavorable operating leverage. The tax burden was 0.779, indicating a normal effective tax burden, while the interest burden of 1.773 was elevated because profit before tax benefited from the ¥0.16bn extraordinary gain; it should not be interpreted as evidence of low debt servicing pressure. The 2.0% ROE and the 0.8% ROIC quality alert remain materially below normal capital-efficiency benchmarks. Profitability is therefore dependent on restoring recurring gross profit and operating income, rather than on further non-operating or extraordinary gains.
Growth Assessment
Top-line momentum was subdued, with nine-month revenue declining 0.2% year on year to ¥24.26bn. The full-year revenue forecast of ¥33.50bn implies a 2.9% year-on-year increase, requiring approximately ¥9.24bn of fourth-quarter sales. The Q3 sales progress rate of 72.4% is 2.6 percentage points below the standard 75% pace, suggesting that the final quarter must deliver a modest sequential acceleration to meet guidance. Operating income progress is 69.0% against the full-year ¥0.30bn forecast, 6.0 percentage points below the standard Q3 pace. The implied fourth-quarter operating income requirement is approximately ¥0.09bn, versus ¥0.21bn earned cumulatively in the first nine months. Ordinary income of ¥0.21bn is already 210.0% of the full-year ¥0.10bn forecast, while net income of ¥0.29bn is 190.7% of the ¥0.15bn forecast. This divergence indicates that full-year guidance embeds a sharp normalization of non-operating and extraordinary items, rather than forecasting a material recovery in the core business. In a pharmaceutical manufacturing context, the 25.8% gross margin and large inventory base indicate that pricing, product mix, procurement costs, and production utilization will be important determinants of earnings recovery. The sustainability of growth is therefore best assessed through recurring operating-profit conversion rather than reported net-income growth.
Financial Health
Liquidity is sound. Current assets of ¥32.46bn exceed current liabilities of ¥14.24bn, producing a 228.0% current ratio and a 176.9% quick ratio. Working capital was ¥18.22bn, providing a substantial near-term liquidity buffer. Cash and deposits of ¥7.01bn were 18.0x short-term loans of ¥0.39bn. In addition, cash exceeds the ¥3.13bn current portion of long-term loans, and total current assets provide ample coverage of near-term obligations. Accordingly, there is no immediate maturity mismatch between current assets and debt falling due within one year. Solvency is more constrained than liquidity: interest-bearing debt was ¥13.34bn, debt-to-equity was 1.71x, and debt-to-capital was 40.9%. The D/E ratio is below the 2.0x aggressive-financing warning threshold, but remains elevated for a business generating only ¥0.21bn of nine-month operating income. Long-term loans of ¥12.95bn account for 24.9% of total assets, making refinancing costs and interest-rate exposure relevant. Short-term loans increased 69.6% year on year to ¥0.39bn, although the absolute increase of ¥0.16bn is small and cash coverage remains very strong. Total liabilities increased ¥2.18bn year on year, while total equity increased only ¥0.09bn to ¥19.25bn; this lifted the balance-sheet reliance on liabilities. The ¥0.47bn provision for directors' retirement benefits, ¥0.13bn net defined-benefit liability, and lease obligations should be included in the broader fixed-obligation assessment.
Notable B/S Changes
Short-term loans: +¥0.16bn (+69.6%) to ¥0.39bn - the percentage increase is significant, although the absolute balance remains small relative to ¥7.01bn of cash and deposits. Finished goods: +¥1.36bn (+23.0%) to ¥7.27bn - elevated finished-goods growth supports the inventory-days alerts and raises demand, obsolescence, and cash-conversion monitoring needs. Work in process: +¥0.81bn (+55.7%) to ¥2.28bn - increased capital tied up in production may reflect production timing or slower conversion into sales. Total liabilities: +¥2.18bn (+7.1%) to ¥32.85bn - liabilities grew faster than equity, increasing reliance on external funding despite a still-adequate liquidity position.
Cash Flow Quality
The working-capital profile is the principal earnings-quality consideration. Accounts receivable were ¥7.82bn and electronically recorded monetary claims were ¥3.88bn, together representing a significant share of revenue and current assets. The 88-day DSO alert is above the 60-day benchmark, indicating slow cash collection relative to sales. Inventories were ¥7.27bn, equal to 14.0% of total assets, and finished goods alone increased 23.0% year on year to ¥7.27bn. Raw materials increased 16.7% to ¥3.80bn and work in process increased 55.7% to ¥2.28bn, reinforcing the indication of elevated capital tied up in production and stock. The 203-day inventory-days alert and the additional 111-day inventory-days alert both point to inventory carrying periods above their respective warning thresholds. The 253-day cash-conversion-cycle alert is substantially above the 120-day benchmark. These metrics raise the risk that cash conversion will lag accounting earnings and that inventory may require close monitoring for obsolescence, demand mismatch, or margin pressure. Electronically recorded obligations of ¥4.75bn partially finance the working-capital requirement, but this does not eliminate the need for timely receivable collection and inventory normalization. Reported net income was also supported by the ¥0.16bn gain on sales of investment securities and ¥0.10bn FX gains, which are less recurring than operating earnings. Earnings quality would improve materially if future profit growth is accompanied by lower inventory days, lower DSO, and a shorter cash conversion cycle.
Dividend Sustainability
The full-year dividend forecast is ¥50 per share, compared with a zero Q2 dividend per share. Based on forecast EPS of ¥41.51, the implied dividend-only payout ratio is approximately 120.5%. This exceeds both forecast earnings and the 100% warning threshold for dividend sustainability. Using issued shares net of treasury shares, the indicated annual cash dividend is approximately ¥0.18bn, compared with full-year forecast net income of ¥0.15bn. The balance sheet has meaningful liquidity, including ¥7.01bn of cash and deposits, so near-term payment capacity is not the central issue. The principal concern is recurring coverage, as nine-month operating income was only ¥0.21bn and interest coverage was 1.22x. The current dividend level therefore appears dependent on balance-sheet capacity and management policy rather than forecast-period earnings coverage. Sustainable dividend support would require a recovery in recurring operating profitability and better working-capital conversion.
Risk Assessment
Business risks include Gross-margin risk: gross margin declined approximately 90 basis points year on year to 25.8%, and the resulting operating margin was below 1%. In pharmaceuticals, pricing pressure, generic competition, procurement inflation, and unfavorable product mix can quickly erode profitability from this low base., Inventory and demand-management risk: inventories totaled ¥7.27bn, while finished goods rose 23.0% year on year. The 203-day and 111-day inventory-day alerts suggest heightened risks of slow-moving stock, write-downs, and production inefficiency., Receivables-collection risk: the 88-day DSO alert exceeds the 60-day benchmark. Slow collection extends the cash conversion cycle and may constrain internally generated funding., FX sensitivity: FX gains of ¥0.10bn equaled 49.3% of operating income. This is material relative to recurring profit and introduces volatility that may reverse with currency movements., Recurring-earnings risk: nine-month net income benefited from a ¥0.16bn gain on sales of investment securities, while core operating income fell 41.7% year on year..
Financial risks include Debt-service risk: interest coverage of 1.22x is below the 2.0x warning threshold. EBIT of ¥0.21bn provides only a narrow cushion over ¥0.17bn of interest expense., Capital-efficiency risk: reported ROE was 2.0% and the ROIC alert was 0.8%, both below levels normally required to support leveraged capital structures over time., Leverage risk: interest-bearing debt was ¥13.34bn and D/E was 1.71x. Although D/E remains below 2.0x, the debt burden is high relative to current operating income., Working-capital funding risk: the 253-day cash conversion cycle increases the amount of capital committed to receivables and inventories, potentially increasing reliance on external financing if operating conditions weaken..
Key concerns include Highest priority is restoration of recurring operating profit, because operating income fell to ¥0.21bn while interest expense was ¥0.17bn., The company should be assessed on gross-margin stabilization and inventory normalization rather than the headline 709.5% increase in net income., The full-year ¥50 dividend forecast implies a payout ratio above 100%, making earnings coverage a key capital-allocation issue., The Q3 sales and operating-income progress rates are below the standard 75% pace, while ordinary and net income exceed guidance because of non-recurring gains..
Investment Implications
Key takeaways include Revenue was resilient but essentially flat, whereas operating income declined 41.7%, confirming a sharp deterioration in operating leverage., The increase in net income was non-recurring in character, driven materially by a ¥0.16bn securities-sale gain and ¥0.10bn FX gains., Liquidity is strong, but low interest coverage makes debt-service capacity sensitive to even modest operating-profit volatility., Inventory, receivable days, and the 253-day cash conversion cycle are central indicators of future earnings and funding quality., Full-year earnings guidance appears conservative relative to nine-month ordinary and net income, but the difference is explained by temporary items rather than a stronger core earnings trajectory..
Metrics to watch include Gross margin and operating margin, Interest coverage ratio relative to the 1.22x Q3 level, Inventory balance, finished-goods growth, and inventory days, DSO and cash conversion cycle, Fourth-quarter revenue and operating income versus the ¥33.50bn and ¥0.30bn full-year forecasts, Foreign-exchange gains or losses and the recurrence of investment-security disposal gains, Dividend coverage relative to forecast EPS of ¥41.51 and DPS of ¥50.
Regarding relative positioning, Relative to standard profitability and capital-efficiency benchmarks, the company is positioned weakly: sub-1% operating margin, 2.0% ROE, and 0.8% ROIC contrast with healthy liquidity ratios. Its balance sheet provides near-term flexibility, but the combination of elevated working-capital intensity, modest leverage, and weak interest coverage makes recurring operating recovery more important than headline net-income growth.